GlaxoSmithKline plc, a pharmaceutical company, in positions of increasing responsibility within the global clinical development and medical affairs areas. After serving in academia at the
University of North Carolina School of Medicine, the UCLA Fielding School of Public Health, and the University of California, Berkeley, Dr. Carter began his pharmaceutical career at Pharmacia Corporation, a pharmaceutical company, in 1993. He
received a B.Sc. in Biochemistry from the University of London, a Ph.D. in Biochemistry from the University of Cambridge, and an M.D. from the University of Miami School of Medicine. Dr. Carter currently serves as the chair of the scientific
advisory board at Bioniz Therapeutics. Dr. Carter has been chosen to serve on our Board due to his significant global experience in research and development in multiple therapeutic areas.
Thomas Woiwode, Ph.D.
Dr. Woiwode has been with Versant Ventures, a venture capital firm, since 2002 in various capacities, serving as a
Venture Partner since 2011 and a Managing Director since 2014. He has served in a number of operating roles over this time, most recently as the chief operating officer of Okairos AG, a biopharmaceutical company, from April 2011 until May 2013, when
Okairos was sold to GlaxoSmithKline plc. Prior to Okairos, Dr. Woiwode co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding chief business officer for three biotech
companies created within Versant. Dr. Woiwode was a research scientist at XenoPort, Inc., a biotechnology company, before joining Versant. Dr. Woiwode serves on the board of directors of CRISPR Therapeutics AG and previously served on the
board of directors of Audentes Therapeutics, Inc. He received a B.A. in English and a B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in organic chemistry from Stanford University. Dr. Woiwode has been chosen to serve
on our Board due to his educational background, his experience as a board member and senior executive of biotechnology and pharmaceutical companies, and his experience as an investor in new life sciences companies.
CLASS II DIRECTORS
To continue in office until the 2019 Annual Meeting of Stockholders
Amber Salzman, Ph.D.
Dr. Salzman has served as our President since May 2016 and as our Chief Executive Officer since October 2016.
Previously, she was a director and the President and Chief Executive Officer of Annapurna Therapeutics SAS, a gene therapy company, from January 2014 until we acquired Annapurna in May 2016. Prior to founding Annapurna, Dr. Salzman served as
Chief Executive Officer of Alophera Therapeutics, Inc., a rare disease company, from January 2012 to December 2013, where she was responsible for overseeing all aspects of the companys business, and as the President and Chief Executive Officer
of Cardiokine, Inc., a specialty pharmaceutical company, from May 2009 until its acquisition by Cornerstone Therapeutics, Inc. in December 2011. Prior to that, as a member of GlaxoSmithKlines research and development executive team,
Dr. Salzman led an organization of approximately 2,000 employees and consultants that planned and managed GlaxoSmithKlines drug-development projects and was accountable for clinical trials that comprised more than 30,000 patients
worldwide. Dr. Salzman is also the president of the Stop ALD Foundation, a patient-advocacy group focused on driving improvements in treatments for patients with adrenoleukodystrophy. She is on the board of directors of the Drexel University
Dornsife School of Public Health and ALD Connect, Inc., which is a consortium of academic, industry and patient advocates. Since April 2017, Dr. Salzman has been on the Board of Trustees of Lankenau Institute for Medical Research.
Dr. Salzman received a B.A. from Temple University and a Ph.D. from Bryn Mawr College. Dr. Salzman has been chosen to serve on our Board due to her executive leadership of Adverum and her knowledge of the research, development and
commercialization of pharmaceutical products in a variety of therapeutic areas that she gained as a former executive at both startup and global pharmaceutical companies, as well as her strong ties to patient advocates and the rare disease community.
Patrick Machado
. Mr. Machado was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its Chief Business
Officer from 2009 to 2014 and as its Chief Financial Officer from 2004 until his retirement in 2014. From 1998 to 2001, Mr. Machado worked with ProDuct Health, Inc., a medical device company, as Senior Vice President, Chief Financial Officer
and earlier as General Counsel. Upon ProDuct Healths acquisition by Cytyc Corporation, a diagnostic and medical device company, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career,
Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado also
9